Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
GLP-1 Market Leade | Eli Lilly dominates the GLP-1 and obesity treatment markets with Mounjaro and Zepbound, driving significant growth despite recent challenges in Q4 2024 |
Pipeline Potential | Explore Eli Lilly's promising pipeline, including Orforglipron, an oral GLP-1 agonist in Phase 3 trials for diabetes and obesity, poised to revolutionize treatment |
Financial Outlook | Analysts project Eli Lilly's price targets between $650 and $1,190, with 2025 revenue forecasts ranging from $58 billion to $61 billion |
Market Expansion | Learn how Eli Lilly plans to capitalize on global markets and potential Medicare coverage for obesity treatments, while navigating supply constraints and competition |
Metrics to compare | LLY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLLYPeersSector | |
---|---|---|---|---|
P/E Ratio | 61.7x | 17.8x | −0.5x | |
PEG Ratio | 0.76 | 0.07 | 0.00 | |
Price/Book | 43.4x | 2.8x | 2.6x | |
Price / LTM Sales | 14.0x | 4.1x | 3.0x | |
Upside (Analyst Target) | 27.2% | 143.2% | 52.6% | |
Fair Value Upside | Unlock | 6.2% | 8.8% | Unlock |